RT recruits the immune system against tumor is important for systemic tumor control. Regression outside the field of radiation after irradiation of one tumor site in the “abscopal effect”. It is a rare but well documented phenomenon that has been reported more frequently in patients with more immunogenic tumor types. RT induction of T cell responses is blocked by immunosuppressive mechanism such as Tregs and MDSCs in the TME. Immunotherapies that block immunosuppressive mechanism or enhance immune activation can work in concert with RT to generate an in-situ tumor vaccine. Studying antigenic targets of immune responses to RT may provide potential combination regimens with standard of care RT.
Screen for drug candidate effects on radiation treated cells
Antigen release by RT treated patient samples
Combination studies of checkpoints and radiation sensitizers